SEC Form 4 · accession 0001628280-26-044266
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sheldon L. Koenig
Officer — President and CEO · Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 4:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001434868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 17, 2026 | S | 53,588 | $3.155 | D | 2,119,111 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares were sold to satisfy tax obligation on vested shares of restricted stock units.